Comprehensive provision of the healthcare system with innovative medicines

MEDIPAL specializes in comprehensive provision with innovative medicines of different pharmaceutical groups, high-tech consumables and medical devices.

In addition to a wide range of products, the company is developing its activities in a number of key areas.

Immunobiology
Immunobiology
Human Normal Immunoglobulin
Human Normal Immunoglobulin (IgG + IgM + IgA)
Human Anti-cytomegalovirus Immunoglobulin
Oncology
Oncology
Drug products for background and targeted therapy
Endocrinology
Endocrinology
Drug products for treatment and control of diabetes and diabetes insipidus
Orphan Diseases
Orphan Diseases
Drug products for treatment and prevention of hereditary angioedema, deficiency of von Willebrand factor and other coagulation factors
Hemostasis Disorders
Hemostasis Disorders
Coagulation factors
Drug products for the correction of hemostasis
Antithrombotic drug products
Obstetrics and Gynecology
Obstetrics and Gynecology
Drug products for prevention of Rh incompatibility
Immunoglobulin Human Antirhesus Rho[D]
Intensive-Care Medicine and Anesthesiology
Intensive-Care Medicine and Anesthesiology
General anesthetics
Anesthetics
Products for enteral and parenteral feeding
Drug products for infusion-transfusion therapy, incl. albumin and blood substitutes
Transplantology
Transplantology
Specific immune globulins (Human Anti-cytomegalovirus Immunoglobulin and Human Anti-HBV Immunoglobulin)
Epidemiology
Epidemiology
Vaccines, toxoids, and specific sera
Antiviral and antibacterial drug products, including those for treatment of Covid-19
Products for Rehabilitation
Products for Rehabilitation
Products for rehabilitation of ostomy patients
Wound and skincare products
Products used in excretory function impairments
Medical Devices
Medical Devices
Products for injections
Products used to provide intravenous access
Infusion systems
Devices for immobilization
Drainage systems

Within our priority areas, we are committed to continuous development and product portfolio expansion.